

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/apm-21-3978">https://dx.doi.org/10.21037/apm-21-3978</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The clinical data of enrolled participants and the detail of diarrhea caused by pyrotinib.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Five years within the publication date.
7	To whom will you share the data?	Medical oncologists
8	For what type of analysis or purpose?	For evaluation on the safety of pyrotinib usage in clinical practice or clinical study.
9	How or where can the data/documents be obtained?	Contact to the corresponding author through E-mail.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.